Management of Upper Respiratory Infections in Children

Supportive Care

The American Academy of Pediatrics recommends ensuring adequate hydration to help thin secretions in children with upper respiratory infections 1, 2
The American Academy of Pediatrics suggests using antipyretics, such as acetaminophen or ibuprofen, to manage fever and keep the child comfortable 1, 2
Gentle nasal suctioning may help improve breathing if nasal congestion is present in children with upper respiratory infections 1, 2
The American Academy of Pediatrics advises avoiding over-the-counter cough and cold medications in children under 6 years, as they lack proven efficacy and carry risk of serious toxicity 1, 2

The American Academy of Pediatrics recommends amoxicillin as the first-choice antibiotic for children under 5 years with suspected bacterial pneumonia 3, 2
The Infectious Diseases Society of America suggests dosing amoxicillin at 50-75 mg/kg/day in 2-3 divided doses for children with suspected bacterial pneumonia 4
Amoxicillin covers the most common bacterial pathogen, Streptococcus pneumoniae, in this age group 3
The American Academy of Pediatrics recommends amoxicillin 50-75 mg/kg/day in 2 doses as preferred treatment for streptococcal pharyngitis 4

The American Academy of Pediatrics warns against prescribing over-the-counter cough and cold medications to children under 2 years of age due to lack of efficacy and risk of serious toxicity, including death 1, 2
Between 1969-2006, there were 54 fatalities associated with decongestants and 69 fatalities associated with antihistamines in young children 2

The American Academy of Pediatrics recommends reviewing the child within 48 hours if symptoms are deteriorating or not improving 1, 2
If cough persists beyond 4 weeks, systematic evaluation using pediatric-specific algorithms is required 1, 2
Red flags requiring immediate evaluation include respiratory rate >50 breaths/min, difficulty breathing, grunting, cyanosis, poor feeding, or signs of dehydration 2

The American Academy of Pediatrics advises against prescribing antibiotics for typical viral URI symptoms without evidence of bacterial infection 1, 2
The American Academy of Pediatrics recommends against performing chest physiotherapy, as it is not beneficial and should not be done 1, 2, 5
The American Academy of Pediatrics warns against using topical decongestants in young children due to narrow therapeutic margin and risk of cardiovascular/CNS side effects 2
The Infectious Diseases Society of America advises against changing antibiotic therapy within the first 72 hours unless the patient's clinical state worsens 3

The American Academy of Pediatrics recommends diagnostic criteria for Acute Bacterial Rhinosinusitis (ABRS), including purulent nasal discharge persisting >10 days, or worsening symptoms after initial improvement, or severe symptoms, with a strength of evidence based on clinical trials 6, 7
The American Academy of Pediatrics suggests first-line treatment for ABRS with amoxicillin, with a dosage of 45 mg/kg/day divided twice daily, or alternative high-dose amoxicillin (90 mg/kg/day) if recent antibiotic use within 4-6 weeks or severe symptoms, based on evidence from pediatric trials 6
The use of amoxicillin-clavulanate (90 mg/6.4 mg per kg/day) is recommended as an alternative in areas with high penicillin-resistant S. pneumoniae prevalence, with consideration of adverse events, according to the American Academy of Pediatrics 6
Clinical trials have shown conflicting results regarding the benefit of amoxicillin-clavulanate over placebo, with one trial demonstrating a 50% cure rate versus 14% with placebo, and another showing no significant difference (83.9% vs 71%, p=0.22), highlighting the need for stringent diagnostic criteria, as reported in Pediatrics and Rhinology 6, 7

The American Academy of Pediatrics advises against prescribing antibiotics for typical viral URI symptoms without evidence of bacterial superinfection, due to the lack of benefit and potential risks, including adverse events and antibiotic resistance 6
The American Academy of Pediatrics recommends avoiding azithromycin as first-line treatment due to inadequate coverage for common URTI pathogens and associated risks, such as QT prolongation, based on evidence from clinical studies 6

The Infectious Diseases Society of America (IDSA) recommends not changing or adding antibiotics within the first 72 hours of therapy unless the child’s clinical condition clearly worsens (e.g., new fever, respiratory distress, or hypoxemia)【8】.

Multiple pediatric randomized trials have shown that a 5‑day course of high‑dose amoxicillin is non‑inferior to a 10‑day course for treating uncomplicated community‑acquired pneumonia in children who demonstrate early clinical improvement【9】.